Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-sheng Wang, Man-Fung Yuen, Qin Ning

Clin Mol Hepatol. 2025;31(Suppl):S134-S164. Published online January 22, 2025

DOI: https://doi.org/10.3350/cmh.2024.0780

View: 3697 Download: 413 Web of Science: 1 Crossref: 2

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 4852 Download: 353 Web of Science: 9 Crossref: 11

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 1751 Download: 194 Web of Science: 2 Crossref: 5

Letter to the Editor

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou

Clin Mol Hepatol. 2025;31(3):e252-e253. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0189

View: 1123 Download: 62

Classification of microvascular invasion of hepatocellular carcinoma: Different standards, common goals: Letter to the editor on “Classification of microvascular invasion of hepatocellular carcinoma: Correlation with prognosis and magnetic resonance imaging”

Wei Chen, Yihui Rong, Tianshi Ma, Weiwei Shi, Wei Chen, Hang Jiang

Clin Mol Hepatol. 2025;31(3):e249-e251. Published online February 18, 2025

DOI: https://doi.org/10.3350/cmh.2025.0167

View: 838 Download: 62

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(3):e239-e246. Published online January 21, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165

View: 934 Download: 69

Snapshot

Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease

Pingping Jin, Xinyi Lu, Daozhen Chen, Yu Chen

Clin Mol Hepatol. 2025;31(3):1100-1102. Published online February 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1090

View: 975 Download: 105

Original Article

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study

Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(3):1084-1099. Published online April 23, 2025

DOI: https://doi.org/10.3350/cmh.2024.1096

View: 1703 Download: 171

HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study

Vincent Wai-Sun Wong, Guy W. Neff, Adrian M. Di Bisceglie, Ru Bai, Junwei Cheng, Meng Yu, Alexander Liberman, Liping Liu, Nadege Gunn

Clin Mol Hepatol. 2025;31(3):1071-1083. Published online April 21, 2025

DOI: https://doi.org/10.3350/cmh.2025.0145

View: 1034 Download: 60

CD36 promotes iron accumulation and dysfunction in CD8⁺ T cells via the p38-CEBPB-TfR1 axis in earlystage hepatocellular carcinoma

Yifei Qin, Fei Huo, Zhuan Feng, Jialu Hou, Yaxin Ding, Quancheng Wang, Yu Gui, Ziwei Yang, Jiali Yang, Gang Zhou, Ling Li, Jianli Jiang, Lingmin Kong, Shijie Wang, Gang Nan, Dingqiao Xu, Xiaohang Xie, Lijuan Wang, Qian He, Ruibin Yang, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu

Clin Mol Hepatol. 2025;31(3):960-980. Published online March 4, 2025

DOI: https://doi.org/10.3350/cmh.2024.0948

View: 1834 Download: 297

Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target

Gu-Wei Ji, Zheng-Gang Xu, Shuo-Chen Liu, Shu-Ya Cao, Chen-Yu Jiao, Ming Lu, Biao Zhang, Yue Yang, Qing Xu, Xiao-Feng Wu, Ke Wang, Yong-Xiang Xia, Xiang-Cheng Li, Xue-Hao Wang

Clin Mol Hepatol. 2025;31(3):935-959. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2024.0895

View: 7683 Download: 362

Review

Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment

Hee Yeon Kim, Mary E. Rinella

Clin Mol Hepatol. 2025;31(3):753-770. Published online April 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0083

View: 1748 Download: 187 Crossref: 1

Deciphering adenosine signaling in hepatocellular carcinoma: Pathways, prognostic models, and therapeutic implications

Huihai Yang, Martina Mang Leng Lei, Longfei Xie, Yinuo Shou, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(3):706-729. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2024.1068

View: 1829 Download: 153 Crossref: 1

Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications

Xindi Ke, Shangze Jiang, Qiaoxin Wei, Minghao Sun, Hang Sun, Mingchang Pang, Mei Liu, Lejia Sun, Huayu Yang, Yilei Mao

Clin Mol Hepatol. 2025;31(3):685-705. Published online January 22, 2025

DOI: https://doi.org/10.3350/cmh.2024.1039

View: 1850 Download: 200 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):e232-e233. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0203

View: 745 Download: 22

Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):e226-e227. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0128

View: 1165 Download: 31

Correspondence

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e208-e209. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1171

View: 1294 Download: 26

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 762 Download: 19 Web of Science: 1 Crossref: 1

Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e186-e188. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0079

View: 876 Download: 37 Web of Science: 1 Crossref: 1

HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Clin Mol Hepatol. 2025;31(2):e163-e165. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.1057

View: 998 Download: 37

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”

Ji Won Han, Dae Won Jun

Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1160

View: 1222 Download: 34

Editorial

Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Nahee Hwang, Sungsoon Fang

Clin Mol Hepatol. 2025;31(2):631-634. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0066

View: 1281 Download: 49 Web of Science: 2 Crossref: 2

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):628-630. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0036

View: 1340 Download: 50 Web of Science: 2 Crossref: 2

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 1175 Download: 43 Web of Science: 2 Crossref: 2

Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”

Eun Sun Jang

Clin Mol Hepatol. 2025;31(2):596-598. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0992

View: 1047 Download: 23 Web of Science: 1 Crossref: 1

Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”

Myeung Gi Choi, Na Young Lee, Ja Hyun Koo

Clin Mol Hepatol. 2025;31(2):592-595. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0971

View: 1756 Download: 92

Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Nilanga Nishad

Clin Mol Hepatol. 2025;31(2):581-583. Published online November 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0942

View: 1302 Download: 44 Web of Science: 1 Crossref: 1

Original Article

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0904

View: 1763 Download: 120 Web of Science: 4 Crossref: 1

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):525-547. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0835

View: 4968 Download: 331 Web of Science: 9 Crossref: 11

Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation

Ester Ciociola, Tanmoy Dutta, Kavitha Sasidharan, Lohitesh Kovooru, Francesca R. Noto, Grazia Pennisi, Salvatore Petta, Angela Mirarchi, Samantha Maurotti, Bernardette Scopacasa, Luca Tirinato, Patrizio Candeloro, Marcus Henricsson, Daniel Lindén, Oveis Jamialahmadi, Arturo Pujia, Rosellina M. Mancina, Stefano Romeo

Clin Mol Hepatol. 2025;31(2):445-459. Published online December 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0642

View: 3078 Download: 367 Web of Science: 2 Crossref: 3

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 12753	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7683	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7187	MAFLD: How is it different from NAFLD?
Viewed By 5739	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5681	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 369	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 354	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search